Heather Peirce, MD
Neuromusculoskeletal Medicine, Sports Medicine · Cumberland, MDNPI 1225043045
Payments from drug & device makers
Across 377 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AbbVie$846
- Sanofi-aventis U.S. LLC$365
- Bayer$263
- plus $1K from 14 others
What the payments were for
- Travel & lodging$1,13816%
- Food & beverage$5,66182%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 28 | $1,739 |
| Lilly USA, LLC | 74 | $1,214 |
| Novo Nordisk | 82 | $1,194 |
| AbbVie | 69 | $846 |
| Sanofi-aventis U.S. LLC | 25 | $365 |
| Bayer | 15 | $263 |
| Boehringer Ingelheim | 13 | $232 |
| Johnson & Johnson | 19 | $149 |
| Dexcom, Inc. | 9 | $148 |
| Astellas Pharma US Inc | 4 | $136 |
| Amgen | 9 | $133 |
| Novartis | 5 | $99 |
| Ultragenyx Pharmaceutical Inc. | 5 | $88 |
| Amarin Pharma, Inc. | 6 | $84 |
| AstraZeneca | 4 | $66 |
| Insulet Corporation | 3 | $57 |
| Abbott | 3 | $52 |
| Acella Pharmaceuticals, LLC | 2 | $36 |
| Shire North American Group Inc | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,041
- Minimed 630G$244
How this compares
Too few neuromusculoskeletal medicine, sports medicine providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 156 | $254,386 |
| TrulicityDulaglutide | 125 | $197,058 |
| JardianceEmpagliflozin | 112 | $155,184 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $71,787 |
| SynthroidLevothyroxine Sodium | 652 | $62,360 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $52,900 |
| TradjentaLinagliptin | 35 | $39,525 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $37,412 |
| MounjaroTirzepatide | 19 | $37,266 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $34,275 |
| JanuviaSitagliptin Phosphate | 21 | $33,030 |
| FarxigaDapagliflozin Propanediol | 29 | $30,400 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $27,029 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $21,396 |
| Humalog Kwikpen U-100Insulin Lispro | 31 | $17,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $1,194 | $283,050200 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,214 | $234,324144 claims |
| Boehringer IngelheimJardiance, Tradjenta | $232 | $194,709147 claims |
| AbbVieSynthroid, Armour Thyroid | $846 | $67,492697 claims |
| AstraZenecaFarxiga | $66 | $30,40029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine, sports medicine providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other neuromusculoskeletal medicine, sports medicine in Cumberland
- David MossChevy Chase$606
- Jasmine ToorBaltimore$428
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.